Centre Hospitalier d'Arras Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2019
NCT03974139
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Arras | Centre Hospitalier d'Arras | Centre Hospitalier d'Arras, INSERM

Active Ingredients

Drugs in Phase 3 Trials (1)

nicotinamide (1 trial)

Drugs in Phase 2 Trials (1)

metformin (glucophage) (1 trial)

Drugs in Other Trials (1)

landiolol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3